Life Extension Final Clerance Sale

KH3



image

image Procaine haematoporphyrin (K.H.3) and its effect on urinary incontinence in the institutionalised elderly
image

A procaine derivative for the treatment of depression in an outpatient population

image

Antioxidant and lipid-lowering effects of the original procaine-based products

image

Successes in novocain therapy in the control of premature ageing

image

The effects of procaine/haematoporphyrin on age-related decline: A double-blind trial

image

The effect of orally administered procaine on physical performance

image

Evaluation of the effect of aslavital and gerovital Hsub 3 therapy on erythropoiesis by the reticulocyte production index

image

Biochemical and pharmacodynamic arguments to support procaine IMAO 'B' type action

image

Central neurotransmitters and aging

image

Gerovital H3 in the treatment of the depressed aging patient

image

A trial of gerovital H 3 in depression during senility

image

The effect of gerovital Hsub 3 treatment on plasma steroids in elderly subjects

image

Peculiarities of chronic degenerative rheumatism in the aged and the efficiency of gerovital Hsub 3 therapy

image

Adjuvant arthritis in rats and the effects of gerovital Hsub 3 therapy

image

Eyeground changes in hypertension in relation to age and eutrophic therapy

image

The influence of gerovital Hsub 3 treatment on platelet adhesiveness

image

Thrombophilic risk factors and prophylaxis of thromboembolic accidents in old people

image

Modifications of humoral syndrome in old patients with atherosclerosis under biotrophic treatment with procaine plus vitamins

image

Theoretical bases of procaine therapy (gerovital Hsub 3 and aslavital) in the prophylaxis of aging

image

Acute pneumopathies in the elderly

image

The effect of procaine derivative agents on lymphocyte blast transformation in elderly subjects with dyslipoproteinemia

image

Longitudinal study of adaptation to aging process in a group of workers treated with gerovital H3

image

Aspects of the prevention of pathologic aging by gerovital Hsub 3 treatment



image

Effects of procaine on synthesis of genetic material and tissue proteins

image

Clinico-functional and histological researches on the kidney in the aged

image

Rosette-forming ability of human T lymphocytes in relation to age and biotrophic treatment

image

Antialbumin antibodies in old agers and the influence of biotrophic treatment with gerovital Hsub 3

image

Experimental methods to induce longevity

image

Results of prophylactic treatment with gerovital Hsub 3 in field practice (gerontological centers). A longitudinal study

image

Electronic spin resonance study on human serum and whole blood in relation to aging, pathology and biotrophic treatment with procaine

image

Local action of procaine in experimental aging of cutaneous tissue

image

Current priorities in the biology of aging

image

An overview of pharmacologic treatment of cognitive decline in the aged

image

The evolution of rat brain and liver acid phosphatase in aging and after Gerovital Hsub 3 treatment

image

Gerovital H3 effects upon human cognitive behaviour and psychomotor capacity

image

Gerovital

image

NADH-dehydrogenase activity in the mitochondrial fraction of rat liver. Gerovital H3 and Aslavital effect on NADH oxidation

image

Neuronal ergastoplasm variation with aging and Gerovital H3 treatment in rats

image

A study on the therapeutic effect of Gerovital H3 in arthrosis in aging patients

image

The biometry of aging

image

Effects of Gerovital H3 therapy on medullary insufficiency in the aging

image

Researches on the antithrombophilic activity of the biotrophic therapy with gerovital Hsub 3 and aslavital

image

Longitudinal therapeutic research on aslavital treatment in aged outpatients

image

Theoretical and practical aspects of chemotherapeutic techniques in the retardation of the aging process

image

Unproven methods of cancer management. Dimethyl sulfoxide (DMSO)

image

The effects of gerovital Hsub 3 treatment on antigen-induced arthritis in rabbits

image

A case of rheumatoid polyarthritis positively managed with gerovital Hsub 3

image

The efficacy of Gerovital Hsub 3 treatment preventively and curatively administered to gerontologically dispensarized workers from the Mineral Oil Equipment Factory, Tirgoviste, Romania

image

A clinical study on the efficacy of gerovital H3 therapy in the management of rheumatoid polyarthritis

image

The effect of Gerovital Hsub 3 and Aslavital on the lipofuscin pigment from old rat brain, heart and testes, evaluated spectrofluorometrically

image

A double-blind study on the antidepressive effects of Gerovital Hsub 3 and Aslavital in the elderly

image

Gerovital H3 in treatment of depression. Preliminary results

image

Isoprinosine (INOSINE PRANOBEX BAN, INPX) in the treatment of Aids and other acquired immunodeficiencies of importance

image

Immunological effects of Isoprinosine as a pulse immunotherapy in melanoma and ARC patients in melanoma and ARC patients

image

Isoprinosine In The Treatment Of Genital Warts

image

Effect of isoprinosine on lymphocyte proliferation and natural killer cell activity following thermal injury.

image

Immunorestoration in children with recurrent respiratory infections treated with isoprinosine.

image

A randomized double-blind study of inosiplex (isoprinosine) therapy in patients with alopecia totalis.

image

Isoprinosine abolishes the blocking factor-mediated inhibition of lymphocyte responses to Epstein-Barr virus antigens and phytohemagglutinin.

image

Isoprinosine as an immunopotentiator in an animal model of human osteosarcoma.

image

One-year follow-up on the safety and efficacy of isoprinosine for human immunodeficiency virus infection

image

Immunotherapy of human immunodeficiency virus infection

image

The efficacy of inosine pranobex in preventing the acquired immunodeficiency syndrome in patients with human immunodeficiency virus infection

image

[Evaluation of the treatment of chronic active hepatitis (HBsAg+) with isoprinosine. II. Immunological studies]

image

[Markers of chronic hepatitis B in children after completion of therapy with isoprinosine]

image

[Course of chronic virus hepatitis B in children and attempts at modifying its treatment]

image

Isoprinosine in the treatment of chronic active hepatitis type B.

image

Immunological effects of isoprinosine as a pulse immunotherapy in melanoma and arc patients


bar



Procaine haematoporphyrin (K.H.3) and its effect on urinary incontinence in the institutionalised elderly

J. CLIN. EXP. GERONTOL. (USA), 1987, 9/1 (43-55)

A randomised double-blind trial of procaine haematoporphyrin (KH3) has been carried out in incontinent elderly residents in Local Authority rest homes. The findings provide further support that procaine haematoporphyrin, also known as K.H.3 may be valuable in the management of elderly people who suffer urinary incontinence.



A procaine derivative for the treatment of depression in an outpatient population

PSYCHOSOMATICS (USA), 1976, 17/2 (96-102)

A double blind study comparing Gerovital H3 against placebo in an outpatient private practice population with diagnoses of depressive disorders was performed. Using a random design, 63 patients were studied whose ages ranged from 45 yr old to 83. Psychometric variables used at pre treatment and post treatment intervals included the Clinical Global Impression, Hamilton Rating Scale for Depression, and the Zung Selfrating Depression Scale. The total dosage for patients who were in the Gerovital H3 treated group was 2100 mg of procaine hydrochloride. Statistical analyses using the T test were performed. The results demonstrated that Gerovital H3 was significantly better than placebo on all three variables measured. This was true for comparisons made within the two treatment groups for pre treatment and post treatment scores, and for comparisons made between the two treatment groups, and for the change scores between groups (Gerovital H3 versus placebo). Various examinations pre- and post treatment were done and will be reported later. A tabulation of adverse reactions showed minimal side effects reported for both the Gerovital H3 treated and placebo treated groups. The authors conclude from the data presented that Gerovital H3 is an efficacious drug in the treatment of mild to moderate depressive disorders in an adult population.



Antioxidant and lipid-lowering effects of the original procaine-based products

Romanian Journal of Gerontology and Geriatrics (Romania), 1996, 18/3-4 (47-61)

This study is concerned with the investigation of the hypolipidemic effect of original procaine - based products: Gerovital H3 (GH3) and Aslavital, in relation to possible modifications of the serum total antioxidant capacity (TAOC) and the erythrocyte susceptibility to peroxidation (ESP). Subjects (88 atherosclerotic patients with a mean age of 67plus or minus10 years old) who had ischaemic heart disease, hypertension, hypercholesterolemia or mixed hyperlipidemia, were randomly assigned in four groups as follows: the diet group (control), the Aslavital group, the GH3 n. f. (new formula) group and GH3 o.f. (old formula) group. Serum lipids and lipoproteins (total cholesterol-TC, low-density lipoprotein cholesterol, LDL- C, high density lipoprotein cholesterol, HDL-C and serum triglycerides, TG), serum TAOC, and ESP were assessed at baseline and after 7 months of treatment. For all three treated groups a significant increase in the serum TAOC and a significant decrease in the ESP were pointed out. In the Aslavital group, there was a significant decrease (-36 plus or minus 16%, p&lt0.02) in serum TG in more than 73% patients. We found out significant decreases in TC (-16plus or minus9%, p&lt0.05 for GH3 n.f. and -12plus or minus6%, p&lt0.05 for GH3 o.f.) and LDL-C (-20plus or minus10%, p&lt0.02 for GH3 n.f. and -18plus or minus9%, p&lt0.02 for GH3 o.f.) for more than 45% patients in both GH3 groups. Only in GH3 o.f. group a slight increase in HDL- C for the patients with TG&gt200 mg/db was obtained. These three original procaine-based products could exert their action on the atherogenesis process by lipid and lipoproteins-lowering effects, procaine action on the erythrocyte membrane or by antioxidant mechanisms.



Successes in novocain therapy in the control of premature ageing

Z. ALTERNFORSCH. (GERMANY, EAST), 1977, 32/3 (267-269)

A group of 173 patients with the diagnosis of systemic arteriosclerosis received a treatment with Novocain, according to the following schedule: 3 times a week i.m. injections of 2% procain 5 ml, that means 12 injections a month in 3-5 series. The results were very encouraging in 46% of the treated patients, in 28% a slight improvement was obtained while in 26% the state was unchanged but not worse. The treatment with Gerovital H3 according to A. Aslans method gave very good results in the treatment of diseases like: heart ischemia, systemic arteriosclerosis, predominant cerebral arteriosclerosis, arteriosclerotic Parkinsons disease; obvious results were also obtained in the treatment of psysical disturbances related to arteriosclerosis. The comparison with the control group (patients with placebo) emphasized the good results of the treatment.



The effects of procaine/haematoporphyrin on age-related decline: A double-blind trial

AGE AGEING (ENGLAND), 1983, 12/4 (302-308)

A randomized, double-blind study of procaine/haematoporphyrin (KH3) has been carried out over two years in a selected population of healthy elderly subjects. The period of study exceeds 500 patient years. The trial population was weighted to contain a larger proportion of subjects aged over 75 years than a standard population; those receiving active KH3 had similar characteristics on entry to those receiving placebo. Over the course of two years, KH3 was shown to be an active substance in that: (a) decrement in the consolidation of new learning was prevented in the treatment group (&lt1.0%, as against 38% in the placebo group); (b) the prevalence of incontinence increased significantly in the placebo group, but not in the active group (P < 0.05); (c) there was a significant increase in grip strength in the active treatment group (+22%, P < 0.01 v. placebo); (d) more adverse reactions were observed on treatment with KH3 (P < 0.005).



The effect of orally administered procaine on physical performance

WIEN.MED.WSCHR. (AUSTRIA), 1973, 123/45 (658-660)

The effect of KH 3 on the circulatory function and reaction power was tested in 60 test subjects in a double blind test over a period of 5 mth. While a significant fall of the pulse blood pressure products in the Vienna test and a significant increase of the reaction power was observed in the group of sports lovers for health, these changes remained insignificant in the top sportsmen. However, it is not possible to indicate a specific point of action of this effect.



Evaluation of the effect of aslavital and gerovital Hsub 3 therapy on erythropoiesis by the reticulocyte production index

ROM. J. GERONTOL. GERIATR. (RUMANIA), 1981, 2/1 (25-35)

Erythropoietic functionality was investigated by means of the reticulocyte production index (RPI) on a group of 40 subjects with no erythrocytary pathologic manifestations, belonging to the sample undergoing treatment. These were compared to a group of untreated controls and to a group of 10 patients displaying various types of anaemias. In the group subjected to the eutrophic treatment according to Prof. Dr. Ana Aslan's method, reticulocyte production index was normal in 35% of the cases, low in 17.5% and high in 47.5%, as compared to the control group, in which it displayed an obvious decreasing tendency (it was normal in 22.5% and low in 77.5% of the cases), pointing to the erythropoiesis depression processes in the elderly. Considering the conclusive results concerning the erythron functionally obtained, this method is recommended as a routine test, a practical and objective criterion for the evaluation of the dynamics of the positive effects induced by Gerovital H(3) and Aslavital eutrophic treatment on erythropoiesis.



Biochemical and pharmacodynamic arguments to support procaine IMAO 'B' type action

ROM. J. GERONTOL. GERIATR. (RUMANIA), 1980, 1/1 (55-61)

The improvement of neuro-psychic functions and particularly of depressive states in the procaine-treated aged was pointed out for the first time by Ana Aslan. Subsequently numerous clinical and experimental researches have demonstrated the action of this substance on the central nervous system. The psychological and electroencephalographic investigations have completed the clinical observations. In the biochemical mechanism of action of procaine an important part is played by its ability to inhibit monoaminoxidase. Based on a series of pharmacodynamic tests, the authors tried to define the type of inhibition. Researches in rats pointed out that procaine antagonises the worsening of conditioned behavior, intensifies and prolongs hyperthermia, delays reserpine-induced hypothermia and does not prevent reserpine-induced palpebral ptosis. These data suggest a B-MAO selective inhibitory effect. Contrary to the classical MAO inhibitors, procaine-based products are well tolerated by the aged patients.



Central neurotransmitters and aging

LIFE SCI. (ENGLAND), 1980, 26/20 (1643-1656)

Although there exist many variations in the neurochemical observations, the major and relatively consistent alterations involving the central neurotransmitters with aging appear to be the decline in the activity of CAs, particularly DA, in certain brain areas. Such decline may be effected due to age-related changes at several levels of neurotransmitter metabolism. In general, with aging, biochemical functions dealing with anabolism appear to decrease, whereas those dealing with catabolism appear to increase. In particular, the age-related alterations in CA neurons include decrease in the activity of synthesizing enzymes, increase or no change in the activity of degrading enzymes, reduced reuptake and reduced receptor activity. While there is a sharp decline of TH activity along with the DA level in the striatum with age, CAT and GAD show only a lesser but significant decline in activity. Thus, one of the striking findings in the aging brain appears to be the progressive imbalance between dopaminergic and cholinergic tone and also between dopaminergic and GABA-ergic tone. This decline in DA activity with aging in certain brain areas such as the substantia nigra could also be partially due to loss of neurons in this area where the DA tracts originate and shrinkage of the tissue in the DA-containing striatum; however, this decline largely reflects decreased activity of the residual cells. Similar loss of cells with aging has also been observed in other brain areas, such as the cerebral cortex of man, monkey and rat and cerebellum of man and animals. Hypothalamus, which along with pituitary plays an important role in the neuroendocrine and autonomic control, also undergoes structural and functional changes in aging. Evidently, such areas in the CNS have been considered to play the key role as a pacemaker in the aging process. The neurotransmitter imbalance in aging may serve as a basis for possible therapy of age-related disorders. Proper correction of the imbalance for single or multiple neurotransmitters may produce beneficial effects. Decline in the central dopaminergic activity with aging indicates the use of DA agonists which may have compensatory roles and show some promise in the therapy of the aged. In animal experiments, two DA agonists, apomorphine and amphetamine, were shown to produce more persistent effect (stereotyped behavior) in the old rats compared to the young ones. In elderly hospitalized patients characterized as having 'Poor Motivational Syndrome', amphetamine produced marked improvement. Possible usefulness of ergot derivatives (e.g., Hydergine, Lergotrile) in dementia and other senile dysfunctions may be due to their DA agonistic effects. Decrease of CAs associated with increased MAO activity in certain brain areas in the elderly, as discussed earlier, may be responsible for depression in the aged. Such depression has been treated with MAO inhibitors and tricyclic antidepressants which raise the CA concentrations. Beneficial effect of Gerovital-Hsub 3, a procaine preparation, in depression in the aged, although controversial, has been ascribed to its weak reversible MAO inhibitory action.



Gerovital H3 in the treatment of the depressed aging patient

PSYCHOSOMATICS (USA), 1974, 15/1 (15-19)

85% of 41 subjects reported some improvement from a series of 12 GH3 intramuscular injections. Their response was prompt and dramatic, but mainly subjective. Most felt a greater sense of well being and relaxation, slept better at night, and many obtained some relief from depression and the discomforts of chronic inflammatory or degenerative disease. Such broad and definite claims of improvement are intriguing and encouraging, but caution in their interpretation is indicated. The possibility of a psychogenic effect cannot be ruled out from the study and could explain the improvement in this group of patients. The need for double blind, controlled studies is apparent. The lowering of the blood cholesterol in 8 of 9 cases of hypercholesterolemia is encouraging and warrants further scrutiny. The relief of chronic pain reported by the medical patients is also worth further investigation.



A trial of gerovital H 3 in depression during senility

CURR.THER.RES. (USA), 1974, 16/1 (59-63)

Ten senile arteriosclerotic patients with features of depression were given Gerovital H 3 (100 to 200 mg) i.m. 3 times weekly for 3 wk. The majority of cases required the maximal dose; no side effects were recorded. The drug was found to have mild euphoriant effect which, however, was partly obscured by the variability in the clinical picture of dementia. It is considered that the most likely mechanism by which the drug brings about its effect is a reversible inhibition of MAO, the levels of which have recently been found to increase with age.



The effect of gerovital Hsub 3 treatment on plasma steroids in elderly subjects

ROM. J. GERONTOL. GERIATR. (RUMANIA), 1981, 2/1 (85-94)

Gerovital Hsub 3 (GHsub 3) was administered to 24 healthy ambulatory volunteers aged 50 to 79 yr. The most important hormonal changes recorded after GHsub 3 treatment were: the first two series of intensive GHsub 3 treatment induced an increase in plasma cortisol (p&lt0.001) followed after the 4th series, at approximately seven months after the initation of the treatment, by a fall of cortisol and 17-hydroxyprogesterone levels; the post-treatment changes of plasma estrone levels in elderly estrone seem to suggest a 'moderating' effect of the GHsub 3 treatment on esterone production; and no significant changes of plasma testerone and DHT were noted in elderly men after the GHsub 3 treatment. A second group investigated in the present study, consisting of 14 ambulatory, chronically GHsub 3-treated subjects, presented normal values of cortisol, 17-OH-P, estrone and estrdiol after long-term GH3sub 3 treatment.



Peculiarities of chronic degenerative rheumatism in the aged and the efficiency of gerovital Hsub 3 therapy

ROM. J. GERONTOL. GERIATR. (RUMANIA), 1982, 3/1 (3-13)

The paper presents the practical experience in chronic degenerative rheumatism based on clinical and radiological studies, both longitudinal and cross-sectional, and the effects of Gerovital Hsub 3 treatment administered to a group of 3,655 patients aged 40-99. The chronic degenerative rheumatism was pointed out as main disease in more than 50% (1,855) of the patients under study; this proves that the disease occupies a major place in the pathology of the aged, with an approximate prevalence of 25:1 in women and localized particularly on the backbone. The basic and local therapy with Gerovital Hsub 3 administered according to Prof. Dr. Aslan's method proved that this drug can influence the vascular, nervous, endocrine and metabolic components involved in the genesis of the rheumatic degenerative process. Thus is justified the clearly positive influence of Gerovital Hsub 3 on slowing down the process of physiological aging and alleviation of clinical phenomena which accompany the onset of rheumatic processes.



Adjuvant arthritis in rats and the effects of gerovital Hsub 3 therapy

ROM. J. GERONTOL. GERIATR. (RUMANIA), 1981, 2/2 (293-299)

Arthritis was experimentally induced in male Wistar rats by a single subcutaneous injection with complete Freund adjuvant (CFA) into the proximal third of the tail. The intensity of the arthritic response was assessed by noting the onset of arthritic signs and measuring plethysmometrically the volume of the hindpaws, before and at different times after CFA injection. To determine the effect of the biotrophic substance, the rats were daily injected intraperitoneally with 4 mg/kg body weight Gerovital Hsub 3 (GHsub 3) during 22 days, beginning one day before injection of the adjuvant. The hindpaws volume was measured before, and 14 and 21 days after CFA administration. The results were compared with those obtained in arthritic untreated controls, injected only with CFA, and the percent inhibition of the inflammatory reaction was calculated. It was noticed that Gerovital Hsub 3 treatment resulted in a lower incidence of arthritic animals with marked articular swelling on the 14th and 21st days, and inhibited significantly, by 36%, the increase of hindpaws volume on the 21st day after CFA injection.



Eyeground changes in hypertension in relation to age and eutrophic therapy

ROM. J. GERONTOL. GERIATR. (RUMANIA), 1982, 3/1 (63-73)

A complex ophthalmological investigation was applied to 258 patients (311 eyes), women and men, their age varying between 39 and 92 yr. The changes produced by the essential arterial hypertension were studied at the level of the eyeground according to age (under and over 60) and to sex, in comparison with similar control groups of patients. Thus, the atherosclerotic changes could be noticed at the level of the eyeground due to age. There was examined the evolution of the changes caused by arterial hypertension under the eutrophic treatment with Aslavital ampoules and pills undergone for 2 years in 28 patients (56 eyes). Arterial hypertension combined with atherosclerosis allowed us to divide the examined group of patients over 60 into 2 subgroups: elderly with essential arterial hypertension - those who have reached an advanced age in spite of arterial hypertension; and elderly with atherosclerotic arterial hypertension - those whose physiological senescence or/and pathological processes caused by senescence induced the setting up of arterial hypertension. Analysing the evolution of eyeground changes in the patients treated with Aslavital, it was revealed that the eutrophic therapy with Aslavital had a positive influence on certain ocular parameters specific for arterial hypertension (track and calibre of the great retinal veins and of macular venules), as well as on certain ocular parameters common to arterial hypertension and atherosclerosis (retinal arterio- and phlebosclerosis). This fact allowed us to appreciate the efficiency of the eutrophic therapy on the cardiovascular apparatus, as well as in general.



The influence of gerovital Hsub 3 treatment on platelet adhesiveness

ROM. J. GERONTOL. GERIATR. (RUMANIA), 1982, 3/1 (57-62)

The authors studied the influence in vitro of Gerovital Hsub 3 treatment on the adhesiveness index of platelets in 22 cases; they noticed a decrease with maximum effect at a concentration of 10sup -sup 6 procaine/ml blood (3.7 X 10sup -sup 6 mM). In vivo, the adhesiveness index, studied in 26 young healthy controls, had an average of 41.0%. The eutrophic treatment with Gerovital Hsub 3 administered in a series of 12 injections, 3 per week, to 44 atherosclerotic subjects aged 50-85, resulted in a significant decrease of platelet adhesiveness, from 57.3% to 42.4% (mean values).



Thrombophilic risk factors and prophylaxis of thromboembolic accidents in old people

ROM. J. GERONTOL. GERIATR. (RUMANIA), 1980, 1/1 (83-92)

The importance of precocious diagnosis of the thrombophilic syndrome and of the prophylaxis of vasculo-thrombotic accidents among the elderly is explained by two major clinical and biological old age characteristics: the ageing dysmetabolism and the wellknown frequency of diseases with thrombogenic potential: atherosclerosis, cardiopathies, chronic breathing insufficiency, azotemia, neoplasias, etc. For appreciating correctly the thrombophilic state and consequently thrombosis risks, the author recommends certain humoral test constellations following the simultaneous investigations of plasmatic hypercoagulability, fibrinolytic activity, physiological anticoagulants and thrombocyte function. There are also discussed the aspects of the real efficiency of the anticoagulant treatment for the elderly, with special reference to heparin and K antivitamins and also to the antithrombophilic prophylactic efficiency of a long therapy with biotropic substances like Aslavital.



Modifications of humoral syndrome in old patients with atherosclerosis under biotrophic treatment with procaine plus vitamins

ROM. J. GERONTOL. GERIATR. (RUMANIA), 1980, 1/1 (73-81)

The authors applied intensive therapy with Aslavital for a relatively short period of time (90 days) to a group of aged atherosclerotic patients and proved the favourable influence of this procaine-based product on most of the troubles specific to the humoral syndrome. The antithrombogenous effect was pointed out by the increased endogenous heparin levels, activation of fibrinolysis, reduction of fibrogenemia, diminution of thrombocytic hyperfunction and normalisation of lipoprotein lipase activity; the antiatherogenous properties of this medication were thus proved.



Theoretical bases of procaine therapy (gerovital Hsub 3 and aslavital) in the prophylaxis of aging

ROM. J. GERONTOL. GERIATR. (RUMANIA), 1980, 1/1 (5-15)

The reduced number and functional capacities of the cells during the aging process induce numerous characteristics of aging. As regards the neurons, the main object is to extend the cellular resources, with the help of psycho-pharmacology. The author proved, 25 years ago, the influence of procaine on the nervous system, by psychological and functional, clinical and experimental investigations. Recently the procaine pharmacology has developed by means of some American authors' researches, among which double-blind studies, concerning the favourable effect of Gerovital Hsub 3 on the depressive moods of the elderly. The connection was proved between the aging process and the intensification of monoaminoxidase activity in the brain, as well as procaine and especially Gerovital Hsub 3 capacity to inhibit MAO and to reduce the aging marks at the level of the central nervous system. The anabolic action of procaine was proved in researches on cell cultures as well as on the animals finding, among others, an improved general trophicity and a prolonged life span. Other results obtained in the field of procaine action mechanisms refer to: the improved nitrogenous balance, favoured ATP synthesis, antioxidating action, intervention in the oxidative phosphorylation, the fat metabolism disturbances of atherosclerosis, the increased speed of nerve condition, the excretion of urinary steroids and metabolites, etc. The ultrastructural studies revealed the contribution of Gerovital Hsub 3 to the stabilization of membranes and of the main cellular organelles, the intensification of cell metabolic activity in the treated cultures. All these lie at the basis of the prophylactic action and therapy of the aging phenomenon. In order to intensify the lipotropic action as well as that on the cerebral aging, the author elaborated a new product, Aslavital. The results of this treatment obtained in the first 9 years of application prove its efficacy in the involutive processes, predominantly cerebral, and in atherosclerosis (especially in the disorders of blood coagulability and lipid metabolism), as well as in the prevention or treatment of complications.



Acute pneumopathies in the elderly

ROM. J. GERONTOL. GERIATR. (RUMANIA), 1980, 1/1 (151-158)

This study was conducted on 226 patients aged 61 to 96, suffering from acute pneumopathies; 23.4% presented normal and 76.6% accelerated aging; 2 to 4 morbid associations were noticed in the last group, with a prevalence of chronic bronchopulmonary and cardiovascular diseases, diabetes, alcoholism, etc. The characteristics of the clinical symptoms were cough with muco-purulent expectoration, moderate or absent fever, thoracic pains, leukocytosis. Functionally, 35% of the patients presented severe respiratory or cardiovascular failure. Bacteriologically, a variable uncharacteristic flora was prevalent in most cases, this pointing out the virus-bacterial mixed etiology. The X ray pointed out that disseminated bronchopneumonias were the most frequent forms; the percentage of lobar pneumonia was lower. A discrepancy was noticed between the dominant and persistent radiologic pattern and the clinical one. The severe forms represented 38.1%, in 43% of the cases the evolution was slow and recurrent, pleuro-pulmonary, cardio-vascular, renal complications occurred in 59.8%; mortality reached 17% and was prevalent with the polymorbid group. The anatomopathological examination pointed out giant cells without hepatization as a peculiarity in the pneumonic deceased patients. The therapy administered was complex and included antibiotics, mucolytics, fluidifiants, cardiotonic agents, bronchodilators, analeptics, as well as diets with hydroelectrolytic additives and vitamins to control the deficits in the aged. The favorable clinical evolution and the lower mortality rate in Gerovital Hsub 3 treated cases were pointed out.



The effect of procaine derivative agents on lymphocyte blast transformation in elderly subjects with dyslipoproteinemia

Romanian Journal of Gerontology and Geriatrics (Romania), 1996, 18/3-4 (29-46)

Various immunological functions and responses are affected by the aging process and among them the proliferative capacity of T cells in response to mitogens. The present study approached this direction of research in a group of elderly subjects selected in conformity with the Senieur protocol and with dyslypoproteinemic syndrome, a factor known to affect the lymphocyte function. The subjects were treated with procaine derivative agents (Gerovital H3 and Asiavital) for a period of 7 months and examined before and after the treatment from lymphocyte blast transformation point of view. The procaine derivative agents have special, properties leading to the cell membrane fluidification, have antioxidant properties and decrease the LDL and VLDL fractions and by those general actions may influence favorably the lymphocyte blast transformation also. Results obtained in the study show the increase of lymphocyte transformation to PHA, Con A and less to PWM after treatment with Gerovital H3 and less with Aslavital.



Longitudinal study of adaptation to aging process in a group of workers treated with gerovital H3

Romanian Journal of Gerontology and Geriatrics (Romania), 1993, 14/4 (85-94)

We followed up from gerontological point of view 264 subjects, workers over 40 years old, from a textile industrial unit (Suveica), of which 205 were longitudinally followed up for 6 years. We constituted two groups: 105 subjects undertaking an eutrophic treatment Gerovital H3 group and 100 non-treated subjects. We did clinical and paraclinical annual examinations, as well as complex psycho-social investigations. We used adaptation tests (Bell) before using the treatment and after 6 years of treatment. We noticed significant differences in scores achieved by subjects in the two groups to adaptation variables: a decrease of sensitivity caused by disease in the treated group as compared to a tendency to increased sensitivity in the persons non-treated with Gerovital H3. Determination of interaction between adaptation and age points out a significant correlation in socio-professional adaptation and professional efficiency in the two groups (r = 0.73) in comparson with r = 0.64). There is a tendency to decreased social-family adaptation in both groups, explained by the changes in family and status within these age groups. The elements related to the analysis of health state point out an increased index of amelioration in degenerative chronic diseases, in the treated subjects, maintainance of work capacity and a decrease of medical absenteeism. We also underline elements regarding the influence of gerontologic following up in preventing some negative phenomena of the aging process in active workers.



Aspects of the prevention of pathologic aging by gerovital Hsub 3 treatment

ROM. J. GERONTOL. GERIATR. (RUMANIA), 1983, 4/1 (31-45)

The outcomes were studied of the treatment with Gerovital Hsub 3 administered over the course of 20 years to 200 patients aged over 45, with a view to prevent pathological aging. The post-treatment evolution of chronic-degenerative pathological processes, health status and psycho-social peculiarities were analysed on the basis of some assessment criteria. Gerovital Hsub 3 treatment had favourable effects on the biochemical, biological and psycho-social parameters, thus being documented as a most important method of preventing pathological aging.



Effects of procaine on synthesis of genetic material and tissue proteins

ROM. J. GERONTOL. GERIATR. (RUMANIA), 1982, 3/1 (89-97)

The results of research on Wistar white rats with regard to modifications of the synthesis of genetic material and tissue protein in the process of aging, and also of the influence of eutrophic treatment with a basis of procaine (Gerovital Hsub 3 and Aslavital Hsub 4), have indicated the following facts: under experimental conditions used, maintenance of DNA synthesis in senescence was invariable in the brain and liver of the rat, while the synthesis of RNA and that of protein diminish progressively as age advances. The ratio r-RNA/t-RNA and also the nucleotidic content are not modified; furthermore fragmentations or depolymerisations do not appear in the molecules of RNA. The eutrophic treatment powerfully stimulates the synthesis of RNA with preponderance of that of t-RNA. The same powerful effect of stimulation of the synthesis is noticeable as well in the case of the tissue proteins. The ratio r-RNA/t-RNA is modified; the nucleotidic content remains invariable.



Clinico-functional and histological researches on the kidney in the aged

ROM. J. GERONTOL. GERIATR. (RUMANIA), 1981, 2/1 (111-115)

The authors present the results of clinico-functional studies conducted on 415 subjects aged 30-105, concerning the degree of kidney involution in relation to the overall process of aging. Histological and histochemical aspects of the kidney in the aged and long-living are comparatively presented, resulting from the investigation of 50 subjects aged 70-105 (28 controls and 22 treated with Gerovital Hsub 3 over a period of 8-14 years). The clinico-functional data pointed out the progressive decrease in the physiological performance of the renosecretory apparatus; generally, the involution of the kidney developed at the same rate as the overall organismic aging. The renal morphofunctional tests used by the authors may be considered as quantitative indicators of kidney involution. The histological and histochemical changes involved over 50% of the parenchyma in the samples under study. The injuries were less marked in Gerovital Hsub 3-treated subjects, being confined to hyalinosis and vascular sclerosis.



Rosette-forming ability of human T lymphocytes in relation to age and biotrophic treatment

ROM. J. GERONTOL. GERIATR. (RUMANIA), 1980, 1/2 (305-308)

Using sheep erythrocyte receptors as membrane markers for the T lymphocytes involved in cell-mediated immunity, the authors investigated age-induced changes and the effect of Gerovital Hsub 3 treatment at the level of the T lymphocyte. Rosette-forming T lymphocyte percentage decreases in untreated subjects with advancing age, but keeps close to that of younger ages in Gerovital Hsub 3-treated subjects, as against controls.



Antialbumin antibodies in old agers and the influence of biotrophic treatment with gerovital Hsub 3

ROM. J. GERONTOL. GERIATR. (RUMANIA), 1980, 1/2 (295-299)

The presence of antialbumin antibodies (AAA) was investigated by immunodiffusion in the sera of 415 subjects aged 40 to 90 years, clinically free of overt hepatic diseases. An increased incidence of AAA (30-40%) was noticed in aged people as compared with healthy young adults (9-16%) suggesting an age-dependent alteration of liver cell function. The AAA incidence was significantly reduced by Gerovital Hsub 3 treatment, i.e. 22% in the 116 treated individuals compared with 32% in the 299 untreated ones.



Experimental methods to induce longevity

ROM. J. GERONTOL. GERIATR. (RUMANIA), 1980, 1/2 (265-271)

The authors studied the effect of Gerovital Hsub 3 on 1840 Wistar rats, half injected since age 2 months, with 4 mg/kg body weight Gerovital Hsub 3: three times a week, for four weeks, followed by one month break, in 6 series a year. The remaining animals were injected with saline solution. A 21.2% prolongation of the life span in males and 8.0% in females was noticed. The functional, biochemical and morphological investigations pointed out the better biological condition of the treated animals in late life, as against controls. The longevity of 5 successive generations was studied in a research on 3.681 Wistar rats. Administration of Gerovital Hsub 3 since early life resulted in the prolongation of the life span in both the treated animals and the untreated offspring belonging to the first generation issued from treated parents. The action of Aslavital was also studied. The results pointed out that this product affects the rhythm of aging and results in a 20.3% prolongation of the life span. On the basis of Hayflick's researches on cell cultures, Officer found that the administration of Gerovital Hsub 3 to the cell cultures resulted in the prolongation of the doubling time with another two generations; culture longevity thus increased. The authors' researches pointed out a 16% prolongation of the life span in secondary cultures of monkey kidney cells, subsequent to Gerovital Hsub 3 administration. The experimental methods of inducing longevity bring about useful information for evaluating the efficacy of the geriatric treatment.



Results of prophylactic treatment with gerovital Hsub 3 in field practice (gerontological centers). A longitudinal study

ROM. J. GERONTOL. GERIATR. (RUMANIA), 1980, 1/2 (237-240)

The results are presented of a 10 year longitudinal study on the prophylactic therapy with Gerovital Hsub 3 on patients aged 45 to 60. The gerontoprophylactic action aimed at pointing out the efficacy of the method Aslan in maintaining or improving the biological potential and preventing precocious aging and chronic degenerative phenomena. The efficacy increased with the duration of the treatment; positive results have been obtained mostly after 2 years of treatment; they were pointed out by the improvement of somatophysiometric indices, decrease in morbidity due to chronic diseases, increase in organismic trophicity, a longer maintained good working capacity.



Electronic spin resonance study on human serum and whole blood in relation to aging, pathology and biotrophic treatment with procaine

ROM. J. GERONTOL. GERIATR. (RUMANIA), 1980, 1/1 (67-71)

The concentration of paramagnetic centres was evaluated by means of electrical spin resonance (e.s.r.) measurements on 110 serum and blood specimens from 30 young (aged 20-39), 36 orthogerous elderly (aged 60-85) and 34 elderly subjects (aged 60-90) with pathological problems (cardiovascular affections). The serum concentration of paramagnetic centers is significantly higher (p&gt0.02) in orthogerous elderly as against young subjects. The difference is also statistically significant (p>0.02) between the serum concentration of paramagnetic centres in the elderly with pathological problems and that of the elderly subjected to the long-term treatment with Gerovital Hsub 3.



Local action of procaine in experimental aging of cutaneous tissue

ROM. J. GERONTOL. GERIATR. (RUMANIA), 1980, 1/1 (63-65)

Electron microscopic studies performed on the rat skin submitted to U.V. rays revealed a less severe deterioration of the skin structures in the animal group whose skin was protected by Gerovital Hsub 3 cream in comparison with the control group. The protective action of Gerovital Hsub 3 was observed at the level of the biologically active cellular layers of the skin as well as in tonofilaments and mitochondria, proving an intensive physiological activity of these cell organelles.



Current priorities in the biology of aging

ROM. J. GERONTOL. GERIATR. (RUMANIA), 1980, 1/1 (17-28)

Aging is an involutive phenomenon progressively affecting all levels of the biological organization: molecular, cellular, tissular, organic and organismic. The aging process does not develop uniformly in time and space, its rate being different for each species, individual, organ and tissue. Between the different phenomena occurring at the same or at different levels of organization, or between mechanisms and effects, there is a feed-back interconditioning. Mention is made of modern concepts on the genetic mechanisms of aging, with emphasis on these which seem to allow a better understanding of the aging process. The author also reports on the contribution of the researches carried out in the National Institute of Gerontology and Geriatrics, Bucharest, in the field of the biology of aging and biotrophic therapy with Gerovital Hsub 3 and Aslavital, products developed by Ana Aslan. A description is given of the research and work on: the increasing degree of collagen polymerization with advancing age; decreasing Fcsup + receptor synthesis in the rat splenocyte with advancing age and its stimulation following therapy; neuronal depletion in the cerebellum; age-induced reduction of structural glycoproteins in the intercellular matrix and their increase in the treated anmimals; decreased rat peritoneal macrophage migration with advancing age; the increased activity of monoamineoxidase in elderly tissues and B type inhibition induced by Gerovital H3; the protective effect of the treatment in cold and stressed, old animals, etc.



An overview of pharmacologic treatment of cognitive decline in the aged

AM. J. PSYCHIATRY (USA), 1981, 138/5 (593-600)

The most widely known substances that have been investigated for treating cognitive deterioration in the aged are cerebral vasodilators, Gerovital H3, psychostimulants, 'nootropics', neuropeptides, and neurotransmitters. The rationale for the choice of specific agents has shifted as our conceptions regarding the origins of cognitive decline have changed; we now know that most cognitive deterioration occurs independently of arteriosclerotic vascular changes. Substances currently being investigated because of their effects on brain electrophysiology, on neurohumoral processes, or on central neurotransmitters show promise.



The evolution of rat brain and liver acid phosphatase in aging and after Gerovital Hsub 3 treatment

ROM. J. GERONTOL. GERIATR. (RUMANIA), 1982, 3/3 (249-260)

No Abstract.



Gerovital H3 effects upon human cognitive behaviour and psychomotor capacity

ROM. J. GERONTOL. GERIATR. (Romania), 1989, 10/4 (277-284)

No Abstract.



Gerovital

DUODECIM (FINLAND), 1977, 93/22 (1434-1438)

No Abstract.



NADH-dehydrogenase activity in the mitochondrial fraction of rat liver. Gerovital H3 and Aslavital effect on NADH oxidation

ROM. J. GERONTOL. GERIATR. (Romania), 1990, 11/3-4 (207-215)

No Abstract.



Neuronal ergastoplasm variation with aging and Gerovital H3 treatment in rats

ROM. J. GERONTOL. GERIATR. (Romania), 1990, 11/1 (33-38)

No Abstract.



A study on the therapeutic effect of Gerovital H3 in arthrosis in aging patients

ROM. J. GERONTOL. GERIATR. (Romania), 1989, 10/2 (93-103).

No Abstract.



The biometry of aging

ROM. J. GERONTOL. GERIATR. (Romania), 1988, 9/4 (409-420)

No Abstract.



Effects of Gerovital H3 therapy on medullary insufficiency in the aging

ROM. J. GERONTOL. GERIATR. (Romania), 1991, 12/1-2 (11-16)

No Abstract.



Researches on the antithrombophilic activity of the biotrophic therapy with gerovital Hsub 3 and aslavital

ROM. J. GERONTOL. GERIATR. (RUMANIA), 1980, 1/2 (195-204)

No Abstract.



Longitudinal therapeutic research on aslavital treatment in aged outpatients

ROM. J. GERONTOL. GERIATR. (RUMANIA), 1983, 4/2 (77-94)

No Abstract.



Theoretical and practical aspects of chemotherapeutic techniques in the retardation of the aging process

ROM. J. GERONTOL. GERIATR. (RUMANIA), 1983, 4/1 (3-11)

No Abstract. <.pr>



Unproven methods of cancer management. Dimethyl sulfoxide (DMSO)

UNITED KINGDOM CA CANCER J. CLIN. (USA), 1983, 33/2 (122-125)

No Abstract.



The effects of gerovital Hsub 3 treatment on antigen-induced arthritis in rabbits

ROM. J. GERONTOL. GERIATR. (RUMANIA), 1984, 5/1 (55-63)

No Abstract.



A case of rheumatoid polyarthritis positively managed with gerovital Hsub 3

ROM. J. GERONTOL. GERIATR. (RUMANIA), 1985, 6/3 (237-240)

No Abstract.



The efficacy of Gerovital Hsub 3 treatment preventively and curatively administered to gerontologically dispensarized workers from the Mineral Oil Equipment Factory, Tirgoviste, Romania

ROM. J. GERONTOL. GERIATR. (RUMANIA), 1987, 8/2 (109-117)

No Abstract.



A clinical study on the efficacy of gerovital H3 therapy in the management of rheumatoid polyarthritis

ROM. J. GERONTOL. GERIATR. (Romania), 1988, 9/4 (449-457)

No Abstract.



The effect of Gerovital Hsub 3 and Aslavital on the lipofuscin pigment from old rat brain, heart and testes, evaluated spectrofluorometrically

ROM. J. GERONTOL. GERIATR. (RUMANIA), 1984, 5/2 (147-155)

No Abstract.



A double-blind study on the antidepressive effects of Gerovital Hsub 3 and Aslavital in the elderly

ROM. J. GERONTOL. GERIATR. (RUMANIA), 1986, 7/2 (79-88)

No Abstract.



Gerovital H3 in treatment of depression. Preliminary results

GERONTOLOGIST (USA), 1973, 13/3(II) (63)

No Abstract.



Isoprinosine (INOSINE PRANOBEX BAN, INPX) in the treatment of Aids and other acquired immunodeficiencies of importance

Cancer Detect Prev Suppl; 1:597-609 1987

The immunopharmacologic effects of Isoprinosine (INPX) have been associated with clinical benefit to the patient in a number of conditions characterized by immunodeficiency of diverse etiology. Immunodepressed homosexuals at risk of developing acquired immunodeficiency syndrome (AIDS) treated with placebo or INPX experienced an increase in the function and number of immunocompetent cells associated with clinical improvement. A multicenter trial designed to confirm these results has demonstrated that INPX produced an increase in natural killer (NK)-cell activity, total T cells, and T-helper cells, with certain effects persisting for months after completion of the 28-day treatment period. INPX-treated patients also experienced clinical improvement and decreased incidence of progression to AIDS. The administration of INPX for longer periods to patients with frank AIDS under a compassionate-use protocol has also proved useful. Clinical benefit associated with INPX treatment has been demonstrated in other patients with a depressed immune response, such as aged patients, cancer patients, severely burned patients, ill patients, and surgery patients. This program of clinical trials supports the therapeutic use of INPX in the treatment of AIDS and other acquired immunodeficiencies of clinical importance.



Immunological effects of Isoprinosine as a pulse immunotherapy in melanoma and ARC patients in melanoma and ARC patients

Cancer Detect Prev Suppl; 1:457-62 1987

Immunomodulatory effect of Isoprinosine are presented in melanoma and HTLV-III/LAV infected patients. Isoprinosine (50 mg/kg) was used as a pulse immunotherapy according to two different schedules: A) 5 days every 15 days and B) 5 days every 15 days for 2 months, then 5 days every 2 months. The patients' immunological profiles were tested before and during the treatment in terms of T-cell subsets, cell number requirement for PHA-induced proliferation, and delayed hypersensitivity reaction to recall antigens. Primary malignant melanoma patients are randomized between surgery alone or associated to isotherapy (schedule A or B). Schedule A,after an initial improvement of surgery-induced immune deficiency, is responsible for an immunodepression, whereas schedule B determines a prolonged restoration in immune responses in melanoma and AIDS related complex or Kaposi sarcoma patients as well. In vitro effects of Isoprinosine on HTLV-III/LAV infection are presented. These data exhibit 1) the need of an immunological follow-up during isotherapy and 2) the immunological benefit of a pulse immunotherapy during acquired immunodeficiencies related to cancer surgery or to HTLV-III/LAV infection in man.



Isoprinosine In The Treatment Of Genital Warts

Cancer Detect Prev; 12(1-6):497-501 1988

Several modes of therapy are presently available for treatment of genital warts. These include use of keratolytics such as podophyllin or trichloroacetic acid, electrocoagulation, cryotherapy, and laser therapy. Responses have not been uniformly successful, however, and particularly in patients with resistant warts there is evidence of impairment of cell-mediated immunity (CMI). In the healing process both humoral and CMI responses are of importance, and indeed it has been reported that in patients with recalcitrant viral warts the lesions disappeared at the same time the CMI response returned to normal. Isoprinosine is an orally administered drug known to have both in vitro and in vivo immunopotentiating activity and has been shown previously to restore toward normal the depressed CMI responses of diverse etiology accompanying a variety of clinical conditions. Recent evidence implicating certain types of genital warts in later development of cervical cancer in females has led to the search for a more effective treatment of this condition. Clinical studies to date involving the use of isoprinosine alone or in combination appear to have established the role of this safe and easily administered oral drug in increasing the chances of total eradication of condylomatous lesions and sparing a high percentage of patients from having to undergo repeated and more traumatic therapies.



Effect of isoprinosine on lymphocyte proliferation and natural killer cell activity following thermal injury.

Immunopharmacol Immunotoxicol (UNITED STATES) 1989, 11 (4) p631-44

The effect of in vivo administration of Isoprinosine (ISO) on, i) the proliferation of splenic lymphocytes in response to the T-cell mitogen, concanavalin-A (Con-A) and, ii) the natural killer (NK) cell cytotoxicity was studied following a full skin thickness burn injury in a rat model. Administration of ISO (100 mg/kg body wt/day) twice daily, resulted in significant augmentation of the proliferative responses of lymphocytes compared to non-treated burned animals, at 7 days post injury. However, it did not effect the lymphoproliferation at 14 days post injury, the time period at which a complete suppression of lymphocyte proliferation was observed in burned non-treated animals. Also, the proliferation of lymphocytes from normal nonburned animals was not affected by treatment with ISO. ISO treatment of the burned animals resulted in a significant increase in the NK cytotoxicity compared to non-treated burned animals. As with Con-A responses, ISO administered to control nonburned animals did not have any effect on NK cell cytotoxicity. Our studies thus indicate that ISO can be a potential immunomodulator of suppressed immune function following thermal injury, particularly in patients whose lymphocyte responses to T cell mitogen Con-A are not completely suppressed.



Immunorestoration in children with recurrent respiratory infections treated with isoprinosine.

Int J Immunopharmacol (ENGLAND) 1987, 9 (8) p947-9

In 27 children, 4-8 years old, with recurrent respiratory infections of the upper and lower respiratory tracts Isoprinosine (ISO) tablets were administered for 7-10 days at daily doses of 50-100 mg/kg. Clinical signs of acute respiratory disease, including temperature abnormalities and subjective complaints, subsided in a short time and the children showed no symptoms for periods ranging from several weeks to several months following the therapy. The children were selected for immunotherapy with ISO on the basis of their low levels of E-rosette forming cells in peripheral blood. Several immune function parameters assessed immediately after treatment with ISO and compared with those obtained before illness and ISO administration. Low levels of T-lymphocytes returned to normal after ISO therapy, B-lymphocyte relative and absolute numbers, however, were not affected by the treatment. Nor were any changes due to ISO found in immunoglobulins, complement components, beta 2-microglobulin and C-reactive protein. Moreover, ISO had no stimulative effect on spontaneous tetrazolium reductase activity of granulocytes but it showed a slight inhibition of their phagocytosis-associated metabolic activity.



A randomized double-blind study of inosiplex (isoprinosine) therapy in patients with alopecia totalis.

J Am Acad Dermatol (UNITED STATES) May 1987, 16 (5 Pt 1) p977-83

Twenty-five of 34 patients with alopecia totalis of at least 1 year's duration and associated defects in cell-mediated immunity completed a randomized, double-blind, placebo-controlled crossover trial of the therapeutic effect of inosiplex, a synthetic immunomodulator. Each patient received 20 weeks of treatment with inosiplex and 20 weeks with placebo in randomized order. Eleven patients were identified clinically as responders to inosiplex in terms of hair regrowth. Scalp biopsy results correlated well with drug therapy. Enhanced immune function was found in the majority of responding patients; however, statistical analysis of the results of the entire patient population revealed limited significant differences. No patient experienced adverse side effects attributable to therapy. These results show that inosiplex is a safe and effective therapy for certain patients with alopecia totalis.



Isoprinosine abolishes the blocking factor-mediated inhibition of lymphocyte responses to Epstein-Barr virus antigens and phytohemagglutinin.

Int J Immunopharmacol (ENGLAND) 1986, 8 (1) p101-6

Acute infectious mononucleosis (IM) is accompanied by measurable abnormalities of immune function, including a transient immunosuppression. The sera of patients with acute IM contain an IgG blocking factor which binds to T-lymphocytes and decreases their responses to antigens and mitogens. The experiments reported herein indicate that isoprinosine, an immunopotentiating agent, can reverse this inhibition of T cells by IM-associated IgG blocking factor. Isoprinosine may be a useful tool in understanding the interactions between blocking factors and lymphocytes; moreover, isoprinosine may be of value in patients with abnormal clinical responses to Epstein-Barr virus (EBV) such as chronic IM or persistent active EBV infections.



Isoprinosine as an immunopotentiator in an animal model of human osteosarcoma.

Int J Immunopharmacol (ENGLAND) 1981, 3 (4) p383-9

The effects of isoprinosine (ISO) on the immune responses (Con A-induced lymphocyte proliferation, monocyte chemotactic responsiveness, and "natural killer" cytotoxicity) of normal hamsters and hamsters with human osteosarcoma (OS) were investigated. Human osteosarcoma was induced in newborn inbred hamsters (LHX/SsLAK) after induction of tolerance in utero. In vitro, ISO increased Con A-induced proliferation of peripheral blood lymphocytes (PBL) from normal hamsters by 23.4-48.9% and from OS-bearing hamsters by 58.1-107.4% over controls (Con A alone). When ISO was administered in vivo by intraperitoneal injection. Con A-induced proliferation of PBL from both normal and OS-bearing recipients in vitro was increased by 50-55% at 1, 3 and 5 days after injection. The chemotactic responsiveness of monocytes from OS-bearing hamsters was also significantly increased (59.1-97.4%) at 1, 3 and 5 days after injection of ISO. Natural killer cytotoxicity was augmented at 1, 3 and 5 days after injection of ISO by 31.7-83.6% in normal hamsters and 54.6-184% in OS-bearing hamsters. These results indicate that ISO can produce a generalized enhancement of immune function in hamsters with OS.



One-year follow-up on the safety and efficacy of isoprinosine for human immunodeficiency virus infection

J. INTERN. MED. (United Kingdom), 1992, 231/6 (607-615)

The safety and clinical impact of isoprinosine in HIV-infected individuals were assessed in a multicentre, randomized, double-blind, 24-week study phase, followed by an optional 24-week open treatment phase. The results of the double-blind phase have been reported. Of 866 HIV-seropositive patients randomized, 832 subjects were eligible for efficacy analysis. On completion of the double-blind phase, 596 patients started open treatment. All patients were evaluated with regard to progression to AIDS and/or death. Within 48 weeks, 10/412 (2.4%) patients assigned isoprinosine and 27/420 (6.4%) patients assigned placebo progressed to AIDS (P = 0.005). Intention-to-treat analysis showed identical results. Viewing the open treatment phase in isolation revealed no difference in progression rates between those treated and those not receiving the drug, perhaps reflecting the higher proportion of patients receiving zidovudine or PCP prophylaxis in the latter group. No severe adverse reactions or toxicities were observed. We conclude that HIV-seropositive patients without AIDS may be safely and effectively treated with isoprinosine.



Immunotherapy of human immunodeficiency virus infection

TRENDS PHARMACOL. SCI. (United Kingdom), 1991, 12/3 (107-111)

HIV infection results in the destruction of the thymus-dependent cellular immune system and death due to opportunistic infection and malignancy. Immunosuppressive influences (other sexually or blood-transmitted viruses, HIV-derived peptides, semen, poor nutrition, drugs, etc.) favor the progression of the disease. Although immunorestorative agents may be expected to delay progression of the disease, John Hadden argues that no agent has yet proven useful in reversing the immunodeficiency in full-blown AIDS. However, two thymomimetic drugs, isoprinosine and diethyldithiocarbamate, inhibit the development of infections in patients with pre-AIDS in large multicenter trials, and preliminary data from trials with two thymomimetic peptides, thymopentin and ImReg-1, in pre-AIDS patients are encouraging.



The efficacy of inosine pranobex in preventing the acquired immunodeficiency syndrome in patients with human immunodeficiency virus infection

NEW ENGL. J. MED. (USA), 1990, 322/25 (1757-1763)

We performed a randomized, double blind, placebo-controlled trial to assess the efficacy and safety of inosine pranobex (isoprinosine) in the treatment of patients with human immunodeficiency virus (HIV) infection but without manifest acquired immunodeficiency syndrome (AIDS). A total of 866 patients were enrolled in 21 centers in Denmark and Sweden. The patients were stratified in three groups according to their CD4+ cell count and randomly assigned to receive either inosine pranobex (1 g three times a day) (n = 429) or matching placebo (n = 437) for 24 weeks. Of the 831 patients who could be evaluated, AIDS developed in 17 in the placebo group as compared with 2 in the inosine pranobex group (P < 0.001; odds ratio, 8.6 (95 percent confidence limits, 2.2 and 52.6)). There were no significant differences between the groups with respect to changes in CD4+ cell count or the development of other HIV-related conditions, with the exception of thrush, which developed in fewer patients in the inosine pranobex group (P = 0.05). No serious side effects were observed. We conclude that treatment with inosine pranobex delays progression to AIDS in patients with HIV infection. The duration of this beneficial effect, the optimal dose, and the mode of action of inosine pranobex remain to be clarified.



[Evaluation of the treatment of chronic active hepatitis (HBsAg+) with isoprinosine. II. Immunological studies]

Pol Tyg Lek (POLAND) Apr 16-30 1990, 45 (16-18) p347-51

A two-month treatment of the chronic active hepatitis (HBsAg+) with isoprinosine produced quantitative and functional T-cells populations in patients with cellular response disorders. Immunological studies have shown that such an effect of isoprinosine lasted for about 4-5 months. Repeated administration of isoprinosine for one month normalized recurrent abnormalities in the monitored immunological parameters.



[Markers of chronic hepatitis B in children after completion of therapy with isoprinosine]

Pol Tyg Lek (POLAND) Mar 15-29 1993, 48 (11-13) p263-4

Fourteen children with chronic active hepatitis B treated with isoprinosine were followed-up for 3-8 years. In no child HBs antigen was eliminated. No seroconversion was noted in children in whom HBe antigen was eliminated. Anti-HBe antibodies were found in 11 children, including 6 children in whom they were present all the time following therapy, and 2 children in whom these antibodies reappeared after an initial elimination. These results suggest that the inhibition of hepatitis B virus replication produced by isoprinosine may be transient. Therefore, longer lasting immunomodulating therapy should be considered.



[Course of chronic virus hepatitis B in children and attempts at modifying its treatment]

Pol Tyg Lek (POLAND) Mar 15-29 1993, 48 (11-13) p258-60

60 children with chronic virus hepatitis B were followed from there to nine years. 34 children received isoprinosine, 6 prednisone and 20 children were without any therapy. There were no cases of death. In 2 cases treated with isoprinosine cirrhosis was found. Eight children with chronic active hepatitis (4 treated with isoprinosine, 1 with prednisone, and 3 without any treatment) had histological recovery. Isoprinosine significantly accelerated seroconversion in HBe system in children with chronic active hepatitis but not in children with persistent, hepatitis. Isoprinosine shortened also the time of normalisation of aminotransferases activity children. Prednisone had no influence on the course of chronic active hepatitis B in treated group.



Isoprinosine in the treatment of chronic active hepatitis type B.

Scand J Infect Dis (SWEDEN) 1990, 22 (6) p645-8

21 patients with chronic active hepatitis B (CAH-B) were treated for 1-2 years with isoprinosine, while another 18 patients served as control group. All patients were initially DNA polymerase (DNAp) and HBeAg positive. Nine (43%) treated patients became persistently negative for DNAp, seroconverted to anti-HBe and showed histological remission on follow-up biopsy. Among simultaneously followed controls 5 (28%) lost DNAp and 4 (22%) also lost their HBeAg. However, only 2 (11%) seroconverted to anti-HBe. Histological improvement was seen in 5 (28%) controls. Thus, it seems that isoprinosine may exert a beneficial effect on the course and outcome of CAH-B.



Immunological effects of isoprinosine as a pulse immunotherapy in melanoma and arc patients

Cancer Detect Prev Suppl; 1:457-62 1987

Immunomodulatory effect of Isoprinosine are presented in melanoma and HTLV-III/LAV infected patients. Isoprinosine (50 mg/kg) was used as a pulse immunotherapy according to two different schedules: A) 5 days every 15 days and B) 5 days every 15 days for 2 months, then 5 days every 2 months. The patients' immunological profiles were tested before and during the treatment in terms of T-cell subsets, cell number requirement for PHA-induced proliferation, and delayed hypersensitivity reaction to recall antigens. Primary malignant melanoma patients are randomized between surgery alone or associated to isotherapy (schedule A or B). Schedule A, after an initial improvement of surgery-induced immune deficiency, is responsible for an immunodepression, whereas schedule B determines a prolonged restoration in immune responses in melanoma and AIDS related complex or Kaposi sarcoma patients as well. In vitro effects of Isoprinosine on HTLV-III/LAV infection are presented. These data exhibit 1) the need of an immunological follow-up during isotherapy and 2) the immunological benefit of a pulse immunotherapy during acquired immunodeficiencies related to cancer surgery or to HTLV-III/LAV infection in man.